scholarly journals Effects of serum 25-hydroxyvitaminD level on decreased bone mineral density at femoral neck and total hip in Chinese type 2 diabetes

PLoS ONE ◽  
2017 ◽  
Vol 12 (11) ◽  
pp. e0188894 ◽  
Author(s):  
Liting Guo ◽  
Zhihong Gao ◽  
Huanqi Ge
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Mineral Density ◽  
Total Hip

scholarly journals Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Ting-ting Cai ◽  
Hui-qin Li ◽  
Lan-lan Jiang ◽  
Hui-ying Wang ◽  
Meng-hui Luo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Placebo Group ◽  
Femoral Neck ◽  
Insulin Glargine ◽  
Mineral Density ◽  
Total Hip

Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and insulin on bone mineral density (BMD) in T2DM. Methods. In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group ( n = 19 ), dulaglutide group ( n = 19 ), insulin glargine group ( n = 10 ), and placebo ( n = 17 ). General clinical data were collected, and BMD was measured by dual-energy X-ray absorptiometry. Results. Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide ( 8.11 ± 0.24 % vs. 7.40 ± 0.16 % , P = 0.007 ), dulaglutide ( 8.77 ± 0.37 % vs. 7.06 ± 0.28 % , P < 0.001 ), and insulin glargine ( 8.57 ± 0.24 % vs. 7.23 ± 0.25 % , P < 0.001 ) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased ( P = 0.027 ), but the magnitude of decrease was less than that in the placebo group; the BMD of L1-L4, femoral neck, and total hip decreased significantly ( P < 0.05 ) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1-4 increased ( P < 0.05 ). Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly ( P < 0.05 ); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased ( P = 0.001 ). Conclusions. Compared with the placebo, GLP-1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP-1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.

scholarly journals Type 2 diabetes and Change in Total Hip Bone Area and Bone Mineral Density in Elderly Swedish Men and Women

2021 ◽  
Author(s):  
Adam Mitchell ◽  
Tove Fall ◽  
Håkan Melhus ◽  
Lars Lind ◽  
Karl Michaëlsson ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Bone Mineral ◽  
Meta Analysis ◽  
Cross Sectional Study ◽  
Bone Area ◽  
Mineral Density ◽  
Cross Sectional ◽  
Total Hip

Abstract Context In a cross-sectional study, we found an association between type 2 diabetes mellitus (T2DM) and smaller bone area together with a greater bone mineral density (BMD) at the total hip. Objective To investigate these associations longitudinally, by studying T2DM status (no T2DM n=1521, incident T2DM n=119 or prevalent T2DM n=106) in relation to changes in total hip bone area and BMD. Methods In three cohorts, the Swedish Mammography Cohort Clinical (SMCC; n=1060, Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; n=483) and Uppsala Longitudinal Study of Adult Men (ULSAM; n=203), with repeat assessment of T2DM status and dual energy x-ray absorptiometry (DXA) measurements of total hip bone area and BMD on average 8 years apart, a linear regression model was used to assess the effect of T2DM status on change in bone area and BMD at the total hip. Results After meta-analysis, the change in bone area at the total hip was 0.5% lower among those with incident T2DM compared to those without T2DM (-0.18 cm 2 [95% CI -0.30, -0.06]). The change in bone area was similar among those with prevalent T2DM compared to those without (0.00 cm 2 [95% CI -0.13, 0.13]). For BMD, the combined estimate was 0.004 g/cm 2 (95% CI -0.006, 0.014) among those with incident T2DM and 0.010 g/cm 2 (95% CI -0.000, 0.020) among those with prevalent T2DM, compared to those without T2DM. Conclusion Those with incident T2DM have a lower expansion in bone area at the total hip compared to those without T2DM.

Bone mineral density in male patients with type 2 diabetes mellitus, with and without hypogonadism

2017 ◽  
Author(s):  
Agathi Vasileiou ◽  
Ioanna Karathanassi ◽  
Parthena Navrozidou ◽  
Marianna Vlychou ◽  
Georgios Koukoulis ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Mineral ◽  
Mineral Density ◽  
Male Patients

scholarly journals Link between vitamin B12, type 2 diabetes mellitus, and bone mineral density in elderly patients

2015 ◽  
Vol 6 (4) ◽  
pp. 120-124 ◽  
Author(s):  
Moatassem S. Amer ◽  
Randa Ali-Labib ◽  
Tamer M. Farid ◽  
Doha Rasheedy ◽  
Mohammad F. Tolba
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Vitamin B12 ◽  
Bone Mineral ◽  
Mineral Density

scholarly journals Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stefana Catalina Bilha ◽  
Letitia Leustean ◽  
Cristina Preda ◽  
Dumitru D. Branisteanu ◽  
Laura Mihalache ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Mineral Density ◽  
Cross Sectional ◽  
The Impact

Abstract Background Despite the increased fracture risk, bone mineral density (BMD) is variable in type 1 (T1D) and type 2 (T2D) diabetes mellitus. We aimed at comparing independent BMD predictors in T1D, T2D and control subjects, respectively. Methods Cross-sectional case-control study enrolling 30 T1D, 39 T2D and 69 age, sex and body mass index (BMI) – matched controls that underwent clinical examination, dual-energy X-ray absorptiometry (BMD at the lumbar spine and femoral neck) and serum determination of HbA1c and parameters of calcium and phosphate metabolism. Results T2D patients had similar BMD compared to T1D individuals (after adjusting for age, BMI and disease duration) and to matched controls, respectively. In multiple regression analysis, diabetes duration – but not HbA1c- negatively predicted femoral neck BMD in T1D (β= -0.39, p = 0.014), while BMI was a positive predictor for lumbar spine (β = 0.46, p = 0.006) and femoral neck BMD (β = 0.44, p = 0.007) in T2D, besides gender influence. Age negatively predicted BMD in controls, but not in patients with diabetes. Conclusions Long-standing diabetes and female gender particularly increase the risk for low bone mass in T1D. An increased body weight partially hinders BMD loss in T2D. The impact of age appears to be surpassed by that of other bone regulating factors in both T1D and T2D patients.

Sign in / Sign up

Export Citation Format

Share Document